EP Patent

EP2394663B1 — Compositions for injectable in-situ biodegradable implants

Assigned to Laboratorios Farmaceuticos Rovi SA · Expires 2021-10-13 · 5y expired

What this patent protects

Patent listed against Risperdal.

Drugs covered by this patent

Patent Metadata

Patent number
EP2394663B1
Jurisdiction
EP
Classification
—
Expires
2021-10-13
Drug substance claim
No
Drug product claim
No
Assignee
Laboratorios Farmaceuticos Rovi SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.